LOX-PP Shown to Have Therapeutic Potential According to GSDM Researchers
GSDM Professor and Director of Oral Biology Research Dr. Philip Trackman’s laboratory has taken their research on the tumor suppressor activity of the lysyl oxidase propeptide, LOX-PP, one step further, showing that LOX-PP could have potential as a therapeutic.
In a paper published in early February by PLoS One, researchers show, “that the recombinant protein can inhibit growth of a pre-existing tumor in mice,” said Dr. Trackman. “This is important, because earlier work showed that if LOX-PP were made by the cancer cells themselves, growth would be slowed.”
Research Assistant Professor Dr. Manish Bais carried out the studies detailed in this paper with the support of Lab Technician Danielle Stephens and Post-Doctoral Researcher Dr. S. Selve Sume. Dr. Sume assisted Dr. Bais with histology and immunohistochemistry methods.
These studies are part of ongoing research collaboration with Tufts University School of Medicine Professor Dr. Gail Sonenshein and BUSM Professor Dr. Kathrin Kirsch, with help from BUSM Professor Dr. Matthew Nugent.
The paper is available in full on the PLoS One website.
Submitted by Laura Mackin.